Compare Tesla, Inc. (TSLA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Tesla, Inc. trades at $380 (market cap $1.49T), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Tesla, Inc. is far larger — about 11.6× Vertex Pharmaceuticals Incorporated's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tesla, Inc. for 88 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TSLA | VRTX | |
|---|---|---|
Market Cap | $1.49T | $128.16B |
Volume | 25,496,215 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $557.96 |
52-Week Low | $298.16 | $407.37 |
Typical Hold Time | 88 Days | 120 Days |
Enterprise Value | $1.46T | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $375.03, down 1.48% with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs $0.50 expected) following two previous beats, with revenue declining to $94.83B in 2025. Analyst sentiment remains divided with 41% buy ratings but a consensus price target of $441.36 suggesting 18% upside. Recent regulatory approval for driver-assistance software in Europe provides near-term catalyst potential.
Tesla faces execution risks amid slowing auto growth but maintains leadership in autonomous driving technology. The stock's premium valuation (P/E 349.82) requires successful expansion into robotics and AI to justify current levels. Near-term pressure from delivery misses contrasts with long-term potential in energy and autonomy markets, creating a high-risk, high-reward investment profile.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
